Table 3. Disease status until the time... | American Society of Hematology

Table 3.

Disease status until the time of allogeneic stem cell transplantation

	Imatinib group (n = 29)	Historical group (n = 33)	P
After induction therapy
CR1 (%)	23 (79.3)	27 (81.8)	.803
Refractory (%)	6 (20.7)	6 (18.2)
After consolidation therapy
Sustained CR1 (%)	22/23 (95.7)	16/27 (59.3)	.003
Relapse (%)	1/23 (4.3)	11/27 (40.7)
After salvage therapy
CR1 (%)	3/6 (50.0)	1/6 (16.7)	.545
Refractory (%)	3/6 (50.0)	5/6 (83.3)
Pretransplantation disease status
CR1 (%)^*	25 (86.2)†	17 (51.5)	.004
CR2 (%)	0	9 (27.3)
Refractory (%)	4 (13.8)	7 (21.2)

	Imatinib group (n = 29)	Historical group (n = 33)	P
After induction therapy
CR1 (%)	23 (79.3)	27 (81.8)	.803
Refractory (%)	6 (20.7)	6 (18.2)
After consolidation therapy
Sustained CR1 (%)	22/23 (95.7)	16/27 (59.3)	.003
Relapse (%)	1/23 (4.3)	11/27 (40.7)
After salvage therapy
CR1 (%)	3/6 (50.0)	1/6 (16.7)	.545
Refractory (%)	3/6 (50.0)	5/6 (83.3)
Pretransplantation disease status
CR1 (%)^*	25 (86.2)†	17 (51.5)	.004
CR2 (%)	0	9 (27.3)
Refractory (%)	4 (13.8)	7 (21.2)

CR1 indicates first complete remission; and CR2, second complete remission.

Sustained CR1 during the consolidation phase plus newly achieved CR1 after the imatinib or salvage chemotherapy

Includes 7 patients with molecular CR